UK COVID-19 Diagnostics industry will see the considerable decline of 30.9% during the forecast period. The government, research institutes, and healthcare firms are collaborating for the development of COVID-19 diagnosis solutions. UK Biobank has recruited 20,000 volunteers, a combination of UK Biobank participants, their adult children, and grandchildren, to produce results that are representative of the UK population. They are providing a finger-prick sample of blood using a kit sent to their home every month for at least 6 months. Antibodies to SARS-CoV-2 in these samples are being measured in a central laboratory at Oxford University which provides evidence of the previous infection with the virus. These first results provide a snapshot for May and June of past SARS-CoV-2 infection, revealing that overall, in the study, 7.1% of the participants had been infected previously. The rate of the previous infection was higher among people of Black (11.3%) and South Asian (9.0%) ethnicity than among those of White ethnicity (6.9%).
Browse the full report description UK COVID-19 Diagnostics Market Size, Share & Trends Analysis Report by Type (Instruments, Reagents & Kits, and Laboratory Testing Services), by Technology Type (PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test), by Sample Type (Oropharyngeal & Nasopharyngeal Swabs, Blood, Urine, Saliva, and Others), and by End-Users (Laboratories, Hospitals, Diagnostic Centers & Clinics, and Research Institutes) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/uk-covid-19-diagnostics-market
On April 07, 2020, as part of the announcement by the UK government to leverage COVID-19 testing, (GSK), AstraZeneca, and the University of Cambridge have entered into a joint partnership to take action for supporting this national effort. Under the collaboration, a new testing laboratory will be established by AstraZeneca, GSK, and the University of Cambridge. The facility will be utilized for high throughput screening for testing of COVID-19 and to explore the utilization of alternative chemical reagents for test kits to support overcome current supply shortages. Along with this new testing facility, AstraZeneca and GSK are working together to offer support for process optimization to the UK national testing centers in Milton Keynes, Alderley Park and Glasgow for COVID-19, offering expertise in robotics and automation to support the national testing system to continuously accelerate capacity over the coming weeks. On 8th April, Novacyt declared that it has collaborated with AstraZeneca, GlaxoSmithKline, and the University of Cambridge to support this national effort. Under the collaboration, Novacyt will ensure an efficient workflow process in the COVID-19 testing facility, as well as deliver its COVID-19 test to produce results data. Novacyt’s COVID-19 PCR test has been developed by Primerdesign, its molecular diagnostics division, based in Southampton, UK. This collaboration has actively supported to meet the testing needs of the country.
Market Coverage
|
Report Elements |
Details |
|
Study Period |
2020-2026 |
|
Segments Covered |
By Type, By Technology Type, By Sample Type, and By End-Users |
|
Key Companies Profiled |
Oxford Nanopore
Technologies Ltd., Abingdon Health Ltd., Mologic Ltd., GlaxoSmithKline PLC,
and AstraZeneca PLC. |
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID
o Most affected segment
o Recommendations
UK COVID-19 Diagnostics Market – Segmentation
By Type
By Technology Type
o Chromatographic Immunoassay
o Fluorescent Immunoassay
o Chemiluminescent Immunoassay
o Enzyme-Linked Immunosorbent Assay (ELISA)
o Neutralization
o Chemiluminescent Immunoassay
By Sample Type
By End-Users
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/uk-covid-19-diagnostics-market